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Abstract
Background: Alphaviral replicon-based vectors induce potent immune responses both when given as viral
particles (VREP) or as DNA (DREP). It has been suggested that the strong immune stimulatory effect induced by
these types of vectors is mediated by induction of danger signals and activation of innate signalling pathways due
to the replicase activity. To investigate the innate signalling pathways involved, mice deficient in either toll-like
receptors or downstream innate signalling molecules were immunized with DREP or VREP.
Results: We show that the induction of a CD8
+ T cell response did not require functional TLR3 or MyD88
signalling. However, IRF3, converging several innate signalling pathways and important for generation of pro-
inflammatory cytokines and type I IFNs, was needed for obtaining a robust primary immune response. Interestingly,
type I interferon (IFN), induced by most innate signalling pathways, had a suppressing effect on both the primary
and memory T cell responses after DREP and VREP immunization.
Conclusions: We show that alphaviral replicon-based vectors activate multiple innate signalling pathways, which
both activate and restrict the induced immune response. These results further show that there is a delicate balance
in the strength of innate signalling and induction of adaptive immune responses that should be taken into
consideration when innate signalling molecules, such as type I IFNs, are used as vaccine adjuvant.
Introduction
Alphaviral replicon-based vectors are attractive vaccine
candidates since they induce strong immune responses
in various animal models. The alphaviral replicon
encodes an alphavirus replicase, an RNA polymerase,
which strongly amplifies the replicon encoded transgene
RNA resulting in high heterologous antigen production.
Initially, the superior immune response induced by
these types of vectors was attributed to abundant anti-
gen production [1,2]. However, the replicase activity also
leads to the formation of double stranded RNA
(dsRNA), which induces activation and cross-priming of
viral associated antigens in CD8a
+ dendritic cells (DCs)
[3]. Hence, it is now becoming increasingly clear that
the immunogenicity of alphaviral replicon-based vectors
is due to activation of innate immune responses, rather
than increased antigen production.
We have previously used alphaviral replicon-based
vaccines administered as viral particles capable of one
round of replication (VREPs) [4]. These VREPs, based
on Semliki Forest virus (SFV), induce strong antibody
and cellular responses in animals [5-10]. SFV, being a
RNA virus, may target several innate signalling pathways
[11,12] including toll-like receptor (TLR) 3 and 7, as
well as cytoplasmic receptors of the RIG-I-like receptor
(RLR) family [13]. We have shown that replication of
VREP generates double-stranded (ds) RNA intermedi-
ates, and that immunization of mice with VREP infected
Vero cells activates the TLR3 pathway leading to
enhanced cross-priming [3]. However, immune activa-
tion was only partly dependent on TLR3, suggesting
that other innate signalling pathways are involved.
Other studies with RNA viruses have suggested that the
MyD88 and TLR3 pathways are targeted [14-16]. How-
ever, recent results indicate that MyD88 and TLR3
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responses after VREP immunization [17]. Thus, it is not
clear which innate signalling pathways that are activated
after VREP immunization. Engagement of TLRs and
RLRs results in production of type I interferon (IFN)
and pro-inflammatory cytokines. The release of type I
IFN has been shown to amplify the innate immune
responses and to be a potent inducer of the adaptive
immune response by activation of DCs, T- and B-cells
[18-21], and has been suggested to be a crucial signal-
ling molecule for the generation of a potent immune
response. We have shown that immunization with
VREP also induces type I IFNs [22]. However, the
impact of type I IFNs on alphaviral replicon-based
immunogens is not clear.
Use of naked DNA for vaccination has gained much
attention, in particular following early promising pre-
clinical results in mice. However, later experiments per-
formed with non-human primates and the first human
clinical trials gave rather disappointing results [23-25].
Conventional DNA (convDNA) vaccines do target a
number of innate signalling receptors, including toll-like
receptors (TLR9) and various cytoplasmic receptors (e.g.
D A Ia n dA I M 2 )[ 2 6 , 2 7 ] ,b u ti tm a yb et h a ta tc o n v e n -
tional delivery doses, these signals are not strong
enough to induce a robust immune response. Inclusion
of elements resulting in apoptosis [28-30] or expression
of interferon regulatory factors [31], events normally
occurring during viral infections, has been shown to
increase the immunogenicity of convDNAs, and suggests
that one possible way to improve convDNA vaccines
would be by mimicking a virus infection.
In our previous studies we have demonstrated that the
immunogenicity of naked DNA is significantly improved
by inclusion of the alphaviral replicon into convDNA
vectors, constructing an alphavirus replicon-based DNA
(DREP) vector [32-37]. This suggests that the viral repli-
case activity could contribute to the enhanced immuno-
genicity of the replicon-based vectors. While
immunization with VREP particles do target various
innate pathways it has not yet been investigated in
head-to-head comparisons if these are the same for
DREP vaccines. In this study we investigated if innate
signalling pathways are important for the immunogeni-
city of alphaviral replicon-based vector immunization.
In this study we show that many of the innate recep-
tors, at least on their own, are dispensable for induction
of CD8
+ T cell responses both after DREP and VREP
immunization. In contrast, IRF3, an important signalling
molecule for the induction of type I IFNs and pro-
inflammatory cytokines, is needed for a fullminant
immune response. Interestingly, the immune responses
are suppressed in both DREP and VREP immunized
mice by type I IFNs. In conclusion, the immune
response is affected by the TLR and RLR downstream
signalling molecule IRF3 and type I IFNs, suggesting
that multiple innate receptors are involved after repli-
con-based vaccine administration.
Materials and methods
Mice and immunizations
MyD88 knock-out (KO) [38], IRF3 KO [39] and corre-
sponding wild type mice, C57Bl/6, and IFN-AR1 KO
[40] mice and corresponding wild type mice, Sv129,
w e r eb r e da n dk e p ta tt h ea n i m a lh o u s ea tK a r o l i n s k a
Institutet, Sweden. The TLR3 KO mice [41] and corre-
sponding wild type mice, C57Bl/6:Sv129, were bred and
kept at the animal house at the Swedish Institute for
Infectious Disease Control, Sweden. Female mice, 6-12
weeks old were immunized intramuscularly (i.m.) under
pathogen-free conditions with DREP-OVA (1, 10 or 50
μg), deltaREP-OVA (50 μg) or VREP-OVA (10
6 infec-
tious units (IU)) in a total volume of 100 μl divided
equally between both hind legs. The DREP-OVA and
deltaREP-OVA DNA were diluted in sterile physiologi-
cal 0.9% sodium chloride solution and the VREP-OVA
viral particles in sterile PBS (Gibco, Invitrogen, Carlsbad,
California). Animal care and treatment were in accor-
dance with standards approved by the local ethics com-
mittee (Stockholms norra djurförsöksetiska nämnd).
DNA and viruses
The DREP-OVA construct was made by cloning the ova
encoding gene, coding for a cytoplasmic non-secreted
form of OVA protein lacking the signal peptide, by BglII
and NotI restriction digestion and T4 DNA ligase reac-
tion. The deltaREP-OVA construct was made from the
DREP-OVA construct by deletion of the region corre-
sponding to the CMV promotor and the SFV replicase
by BamHI restriction digestion, Klenow fill-in reaction
and AseI restriction digestion. The CMV promoter from
the pBK-LacZ plasmid was inserted into the deltaREP-
OVA construct by NheI restriction digestion and Kle-
now fill-in reaction and AseI restriction digestion. All
enzymes were obtained from NE Biolabs, Ipswich, MA.
Plasmids were purified with Endotoxin free Mega-prep
kit (Qiagen, Hilden, Germany) and preparations with
endotoxin levels <0.1EU/μg DNA were used for immu-
nization. The SFV two-helper RNA system has been
described previously [42].
ELISpot
IFN-g ELISpot analysis was performed on freshly iso-
lated splenocytes as describedp r e v i o u s l y[ 1 0 ] .S p l e n o -
cyte single-cell suspensions were treated with Red Blood
Cell lysing buffer and re-suspended in RPMI media sup-
plemented with 2 mM L-glutamine, 2 mM Penicillin-
Streptomycin (all from Sigma-Aldrich, St. Louis, MO)
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(complete media). Splenocytes (2 × 10
5) from individual
mice were added to Multiscreen IP plates (Millipore,
B i l l e r i c a ,M A )c o a t e dw i t ha n t i - m o u s e - I F N - g monoclo-
nal antibody (AN18) (Mabtech AB, Nacka strand, Swe-
den) and stimulated with media or 2 μg/ml OVA
peptide (SIINFEKL) (Proimmune, Oxford, UK) or 2 μg/
ml Concanavalin A (Sigma-Aldrich, St. Louis, MO) for
20 hours. The plates were thereafter developed with bio-
tinylated anti-mouse-IFN-g monoclonal antibody (R4-
6A2) (Mabtech AB, Nacka strand, Sweden), Vectastain
Elite ABC kit (Immunkemi F&D AB, Järfälla, Sweden)
and AEC substrate (Sigma-Aldrich, St. Louis, MO). The
spots were counted using an ELISpot reader (Axioplan 2
Imaging; Zeiss) and expressed as spot forming cells
(SFC) per 10
6 splenocytes. A value equal to or greater
than 55 spots per million splenocytes in the peptide
wells is regarded a positive IFNg response. Mice with
media responses higher than 50 spots in the IFNg ELI-
Spot were omitted from further analysis.
Statistics
Statistical analysis was performed using the GraphPad
Prism 5 software (GraphPad Software Inc., La Jolla, CA).
To test for statistical significance nonparametric two-
tailed Mann-Whitney analysis was performed.
Results
Induction of CD8
+ T cell responses after deltaREP and
DREP immunization
We have previously demonstrated that SFV-based
D R E P sa r em o r ei m m u n o g e n i ci nc o m p a r i s o nt oc o n -
vDNA vectors. However, the different backbone compo-
sitions between the vectors were not considered in
those studies [32,33]. To create a convDNA-like vaccine
vector to be compared with DREP, a deltaREP vector
was constructed by deleting the replicase region from
DREP (Figure 1A). While the vectors certainly have a
significant size difference, this strategy was chosen as a
best effort to be able to compare vectors with (DREP)
or without (deltaREP) replicase activity, sharing the
same backbone. To be able to compare the immuno-
genicity of DREP vs deltaREP, the ova gene was inserted
into both vectors (Figure 1A). In DREP the full-length
RNA replicon is expressed from the CMV promoter,
whereas the OVA protein is expressed by the viral repli-
case from the subgenomic promoter. In contrast, in the
deltaREP construct the OVA protein is expressed
directly under the CMV promoter. When transfected
into BHK cells at similar mass (μg), both plasmids
expressed the OVA antigen in similar amounts per cell
(data not shown).
To compare the immunogenicity of the two DNA vac-
cines, C57Bl/6 mice were immunized with 50 μgo f
DNA and the splenic OVA-specific CD8
+ T cell
responses were measured by IFNg ELISpot 10 days post
immunization. After deltaREP-OVA immunization, only
a few mice responded to the Kb-restricted OVA SIIN-
FEKL peptide. In contrast, all mice responded to DREP-
OVA immunization, with significantly higher numbers
of IFNg producing CD8
+ T cells (p < 0.001) (Figure 1B).
This result confirms previous studies that DREP is
indeed more immunogenic than deltaREP (convDNA
vaccines) [32,33].
Replicon induced CD8
+ T cell responses in the absence of
TLR signalling
Earlier studies investigating innate signalling pathways
by replicon vectors have used VREP particles, whereas it
has not been investigated in parallel if the same innate
signalling pathways are activated by DREP. In order to
investigate the involvement of toll-like receptor (TLR)
and RIG-I-like receptor (RLR) family signalling in DREP
and VREP induced immunity, we used TLR knock-out
(KO) mice or mice lacking innate signalling molecules
presumingly activated by VREP and DREP vectors. As
alphaviral replicon-based vectors are known to generate
Figure 1 Schematic representation of constructs and CD8
+ T
cell responses induced after deltaREP-OVA and DREP-OVA
immunization. (A) Illustration of VREP-OVA, DREP-OVA and
deltaREP-OVA constructs. SP6 = SP6 RNA-polymerase promotor,
CMV = cytomegalovirus promotor, REP = SFV replicase, sp = SFV
subgenomic promoter, OVA = ovalbumine gene, ori = pUC origin,
amp = ampicillin, pA = SV40 late polyadenylation signal, kan =
kanamycin. Dotted lines denote deletion of REP from DREP-OVA to
generate deltaREP-OVA. (B) OVA-specific CD8
+ IFNg T cell responses
in freshly isolated splenocytes 10 days after immunization with
DREP-OVA (black circles (●)), deltaREP-OVA (black squares (■)) or
naïve (black triangles (▲)) C57Bl/6 mice, measured by ELISpot. Values
are expressed as numbers of IFNg spot forming cells (SFC) per
million splenocytes. Each symbol represents an individual mouse
and the group median values are indicated by bars. Data were
pooled from two experiments with 5 to 8 mice per group (B). The
statistical difference between the groups were p < 0.001 (***).
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[3,43], we first analyzed immune responses in wild type
mice and TLR3 KO mice immunized with DREP-OVA
or VREP-OVA. The OVA-specific CD8
+ T cell IFNg
response was measured in the spleen 10 days post
immunization. No statistical significant difference was
detected between the wild type and KO groups of mice
after DREP-OVA or VREP-OVA immunization,
although there was a tendency towards lower responses
in the TLR3 KO groups (Figure 2A).
Another possibility is that TLR7 signalling could be
involved, since DREP produces single-stranded RNA in
the transfected cell. We therefore employed MyD88 KO
mice which abolish signalling through TLR7. Again, we
found no differences between wild type and MyD88 KO
DREP-OVA immunized mice, suggesting that MyD88
dependent pathways, such as the TLR7 signalling path-
way, are not crucial for generation of a strong CD8
+ T
cell response (Figure 2B). Yet another TLR that is
signalling via MyD88 and might be targeted by DREP,
since DREP is administered as naked DNA, is TLR9.
However, no significant difference was found between
wild type and TLR9 deficient mice (data not shown).
Taken together, TLR3 and MyD88-dependent recep-
tors are not crucial for the induction of a CD8
+ Tc e l l
response after VREP and DREP immunization.
Replicon induced CD8
+ T cell responses in the absence of
IRF3 signalling
RNA produced in viral infected cells not only targets the
TLR3 pathway, but also signals through the RIG-I-like
receptor (RLR) family, resulting in the induction of type
I IFNs and pro-inflammatory cytokines via IRF3. It has
recently been shown that VREP is recognised by the
RLRs, MDA5 and RIG-I [44]. We have recently shown
that lack of IRF3 results in reduced type I IFN levels
and delayed type I IFN synthesis by VREP in DCs in
vitro [22]. To investigate the importance of IRF3 in vivo
we immunized wild type and IRF3 KO mice with DREP-
OVA or VREP-OVA, and the OVA-specific CD8
+ T cell
responses were measured 10 days post-immunization.
There was a tendency towards lower responses in the
IRF3 KO mice compared to wild type mice after DREP-
OVA immunization, although there was no statistical
significant difference (Figure 3). In contrast, VREP-OVA
immunization induced statistically significantly lower
level of IFNg producing OVA-specific CD8
+ T cells in
IRF3 KO mice compared to wild type mice (p < 0.05)
(Figure 3), indicating that lack of type I IFN and pro-
inflammatory cytokines reduce the level of the immune
response.
Figure 2 OVA-specific CD8
+ T cells in spleen 10 days after
replicon immunization in wild type, TLR3KO and MyD88KO
mice. The CD8
+ T cell responses were measured in wild type, TLR3
KO (A) and MyD88 KO (B) mice. The numbers of OVA-specific CD8
+
T cells were measured by IFNg ELISpot in wild type (black circles
(●)), KO (open circles (○)) and naïve (black squares (■)) mice. Data
were pooled from two experiments with 3 to 5 mice per group (A)
and from three experiments with 5 to 10 mice per group (B). Values
are expressed as numbers of IFNg SFC per million splenocytes. Each
symbol represents an individual mouse and the group median
values are indicated by bars. No statistical difference was detected
between the groups of mice.
Figure 3 OVA-specific splenic CD8
+ T cell responses 10 days
after replicon immunization in wild type and IRF3KO mice. The
CD8
+ T cell responses were measured in wild type (black circles (●)),
IRF3 KO (open circles (○)) and naïve (black squares (■)) mice, 10
days post-immunization. The numbers of OVA-specific CD8
+ T cells
were investigated by IFNg ELISpot. Data are pooled from four
experiments, with 5 to 10 mice per group. Values are expressed as
numbers of IFNg SFC per million splenocytes. Each symbol
represents an individual mouse and the group median values are
indicated by bars. The statistical difference between the groups
were p < 0.05 (*).
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+ T cell responses in the absence of
the type I interferon receptor
Type I IFNs have been shown to be potent inducers of
both innate and adaptive immune responses [18-21] and
we have previously shown that VREP strongly induces
type I IFNs in vivo [22]. Type I IFNs have certainly been
considered as vaccine adjuvants [45] and IFN stimulatory
elements (IRF3, IRF7, TLR9) combined in/with con-
vDNA vaccines have resulted in significantly increased T
cell responses [31,46,47]. Since mice lacking IRF3 did
show a reduced capacity to induce a CD8
+ T cell
response and IRF3 is crucial for the generation of type I
IFNs, we wanted to investigate whether IFN type I is
important for the immune effect by VREP and DREP.
Moreover, the effect of several TLRs (TLR3, 7 and 9) and
RLRs converge into a type I IFN response. Therefore, we
utilized mice lacking a functional IFNa/b receptor (IFN-
AR1 KO mice), rendering these mice unresponsive to
type I IFNs. Wild type and IFN-AR1 KO mice were
immunized with DREP-OVA or VREP-OVA and the
OVA-specific CD8
+ T cell responses were analyzed 10
days post-immunization. Surprisingly, the IFN-AR1 KO
mice showed significantly higher T cell responses in
comparison to wild type mice, both after DREP-OVA (p
< 0.05) and VREP-OVA (p < 0.05) immunization (Figure
4A), indicating that type I IFNs suppress the immune
response. To investigate if there was a lower dose limit
where DREP-OVA would not induce suppressive
amounts of type I IFNs, wild type and IFN-AR1 KO mice
were immunized with lower doses of DREP-OVA (1 μg
and 10 μg in addition to 50 μg, used elsewhere in the
study). From these experiments it became clear that type
I IFN did have a suppressive effect at higher DNA doses,
as the numbers of OVA-specific CD8
+ IFNg producing T
cells in the wild type mice reached a plateau at doses
exceeding 10 μg DREP-OVA (Figure 4B). In contrast, the
CD8
+ T cell response increased with escalating doses of
DREP-OVA in IFN-AR1 KO mice, resulting in signifi-
cantly higher level of IFNg producing CD8
+ T cells in
I F N - A R 1K Om i c ec o m p a r e dt ow i l dt y p em i c ea tt h e
dose of 50 μg DREP-OVA (p < 0.01).
Since lack of the type I IFN receptor had a pro-
nounced effect on the primary T cell response and sev-
eral reports have shown that type I IFNs are important
for the maintenance of memory cells [48,49], we next
investigated whether lack of the type I IFN receptor had
any effect on the memory pool. Wild type and IFN-AR1
KO mice were immunized with DREP-OVA or VREP-
OVA and five weeks post immunization, the splenic
memory response was analysed by IFNg ELISpot (Figure
4C). As was the case in the primary response, statisti-
cally significantly higher numbers of OVA-specific IFNg
producing CD8
+ T cells were detected in IFN-AR1 KO
mice in comparison to wild type mice, both after DREP-
OVA (p < 0.01) and VREP-OVA (p < 0.001) immuniza-
tion (Figure 4C). These results indicate, in contrast to
what has previously been suggested [48,49], that the
memory CD8
+ T cell pool is maintained in the absence
of type I IFN signalling.
Figure 4 OVA-specific CD8
+ T cells in spleen after replicon
immunization at primary peak and memory responses in wild
type and IFN-AR1 KO mice. The CD8
+ T cell response was
measured 10 days (A) and (B) and five weeks post-immunization (C),
in wild type (black circles (●)), IFN-AR1 KO (open circles (○)) and
naïve (black squares (■)) mice. The numbers of OVA-specific CD8
+ T
cells were measured by IFNg ELISpot (A-C). In (A) and (C) mice were
immunized with 50 μg DREP-OVA and in (B) with 1, 10 or 50 μg
DREP-OVA. Each symbol represents an individual mouse and the
group median values are indicated by bars in (A) and (C). In (B) the
group median values are indicated by circles. Values are expressed
as numbers of IFNg SFC per million splenocytes. Data are pooled
from four experiments, with 5 to 10 mice per group (A) and two
experiments with 10 mice per group (B), and three experiments
with 5 to 10 mice per group (C). The statistical difference between
the groups were p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***).
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nalling pathways are not crucial for the induction and
activation of CD8
+ T cell responses after DREP and
VREP immunization. However, IRF3, downstream of
both TLR and RLR signalling pathways and important
for the generation of type I IFNs and pro-inflammatory
cytokines, was required for a potent T cell response
after VREP immunization, with a similar trend in DREP
immunized mice. In contrast, type I IFNs has a suppres-
sing effect on the T cell response both after DREP and
VREP immunization.
Discussion
I nt h i ss t u d yw ew a n t e dt oc h a r a c t e r i s ew h a tp o s s i b l e
innate signals could form the basis of the enhanced
immunogenicity of DREP and also to investigate if
alphaviral replicons, delivered as DNA (DREP) or as
viral particles (VREP), activate the same innate signalling
pathways, a comparison that has not previously been
done.
DREP vectors have been shown to induce stronger
immune responses in comparison to convDNA vectors
[32-37]. However, in those studies the different back-
bones in the vectors were not considered. In this study
we constructed two new vectors, DREP-OVA and del-
taREP-OVA, containing the same backbone, and com-
pared their immunogenicity in mice. We confirmed that
indeed DREP is more immunogenic than deltaREP on a
per dose basis, despite the potential advantages for del-
taREP, such as size. The size difference is in favour for
the deltaREP construct, since a smaller plasmid size
generates a higher transfection efficacy, as well as higher
numbers of plasmid copies per μgi nc o m p a r i s o nt oa
bigger plasmid, such as DREP. Since the superior
immune effects induced by DREPs does not depend on
unusually high antigen expression levels ([1,2,32] and
data not shown), it is probably mediated by a more
potent activation of innate immune responses.
In this study we found that the CD8
+ T cell responses
induced by DREP or VREP immunization were similar
in wild type, TLR3 and MyD88 deficient mice. In accor-
dance with this, it was recently shown that TLR3 is not
crucial for the generation of a CD8
+ T cell response
after DREP immunization [50] and this also confirms
our earlier results that the T cell responses are not
dependent on TLR3, nor MyD88, after VREP immuniza-
tion [17,22]. In contrast, we have previously shown that
the TLR3 signalling pathway is needed for VREP-
infected cells to induce CD8
+ T cell responses in vivo.
However, these results were obtained in a xenogenic
model in which VREP infected Vero cells, lacking type I
IFN production, were used for immunization [3]. Hence,
our present results suggest that the TLR3 pathway is
dispensable in vivo when type I IFN is present, induced
by multiple signalling pathways after DREP and VREP
immunization.
TLR3 signalling, as well as RLR signalling pathways,
lead to activation of IRF3, which is known to play a cri-
tical role in antiviral responses [51,52] and crucial for
induction of type I IFNs as well as pro-inflammatory
cytokines. Interestingly, the CD8
+ T cell response was
significantly lower in the absence of IRF3 after VREP
immunization, with a similar trend detected after DREP
immunization, albeit not statistically significant. These
results indicate that replicon induced RNAs are impor-
tant activators of innate signalling pathways and adap-
tive immune responses. In accordance, it was recently
published that Chikungunya virus, an other alphavirus,
activates IRF3 via interferon promoter stimulator 1 (IPS-
1), a signalling molecule downstream of the RLRs [53].
It further indicates that multiple innate signalling path-
ways, compensating for each other, are activated after
DREP and VREP immunizations, since the T cell
response was not affected in single TLR KOs and/or
that RLRs play a bigger role than TLRs in replicon
induced immunity. In agreement, it was recently pub-
lished that adenoviral vaccine vectors, which equally to
alphaviral vaccine vectors induce strong immune
responses, activate multiple innate signalling pathways
[54]. Moreover, yellow fever vaccine 17D (YF-17D) is
regarded as one of the most effective live attenuated
vaccines available [55] and has been shown to activate
several innate signalling pathways such as TLR2, 7, 8
and 9. Hence, it might very well be that activation of
multiple innate signalling pathways is a feature of potent
vaccines. The reason why we do detect a significant dif-
ference between IRF3KO and wild type mice after
VREP-OVA immunization, merely detected as a similar
trend after DREP-OVA immunization, is most probably
due to differences in transfection/infection efficacy.
DREP-OVA is mechanically forced into the muscle cells
during injection whereas VREP-OVA is actively infect-
ing the cells, most likely leading to a more effective and
more reproducible antigen delivery into the cells by
VREP-OVA, generally detected as less variation between
the immunized mice.
The signalling of several TLRs (TLR3, 4, 7 and 9) and
RLRs converge into a type I IFN response. Type I IFNs
encompass a multitude of stimulatory effects on the
adaptive T cell response including activation of DC
function, promotion of cross-priming and stimulation of
memory T cells [18-21]. We have previously shown that
VREP is a potent inducer of type I IFN [22]. In the pre-
sent study we observed that the CD8
+ T cell response
was stronger in mice lacking a functional type I IFN sys-
tem, and that this balance was maintained in the mem-
ory response. These results indicate that type I IFNs
suppress the immune response and that the memory
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+ T cell pool is maintained in the absence of type I
IFN signalling, in contrast to what has previously been
suggested [18-21,48,49]. Moreover, it has previously
been reported that splenocyte cultures from DREP
immunized IFN-AR1 KO mice produce lower levels of
IFNg in vitro, in comparison to splenocytes from wild
type mice [56]. However, our dose titration experiment
showed that the T cell responses linearly increased with
higher doses of DREP in the IFN-AR1 KO mice
whereas, in the wild type mice, the immune responses
did not increase at doses higher than 10 μgo fD R E P .
This suggests that type I IFN is only stimulatory until a
certain threshold level has been reached. This is in
agreement with earlier findings that type I IFNs has a
stimulatory effect on CD8
+ T cell responses at low
doses, whereas at higher doses the cytotoxic response
was suppressed [57]. The IRF3KO mice, in contrast to
the IFN-AR1 KO mice, are defective in production of
both type I IFNs and pro-inflammatory cytokines.
Hence, the lower T cell response detected in the
IRF3KO mice could be due to differences in other cyto-
kines than type I IFNs, which compensate for the lack
of type I IFNs in the IFN-AR1 KO mice.
The increased T cell response in the IFN-AR1 KO
mice could have several explanations, such as abundant
antigen production and/or the presence of more innate
receptor ligands due to non-restricted RNA replication,
as RNA viruses are prone to inhibition of replication by
type I IFN. In agreement, plasmid DNA transgene
expression has been shown to be inhibited by type I
IFNs [58]. During a viral infection type I IFN induces an
antiviral state in yet uninfected cells, thus prohibiting
further spread of the infecting agent. However, in our
case, replication of neither vector (VREP or DREP)
results in production of new infectious particles. Thus,
type I IFN mediated antigen or RNA replication sup-
pression have to be in an autocrine fashion. However,
Vero cells infected with VREPs and treated with type I
IFN at different time-points post-infection expressed
similar amounts of VREP encoded protein, indicating
that type I IFN does not suppress the antigen expression
level in the infected cell per se (data not shown). More-
over, we have previously shown that within a few hours
after transfection, DREP and VREP replication will
result in a type I IFN/PKR mediated shutdown of host
protein synthesis, without affecting production of the
vector encoded antigen in vitro [59-61]. In addition, we
have also shown that replication of a VREP mutant, that
induces high levels of type I IFNs, was not suppressed
in comparison to wild type VREP in vitro [62]. More-
over, by increasing the DREP-OVA dose, antigen and
innate receptor ligand load increase, but nevertheless
the immune response does not increase in wild type
mice immunized with doses exceeding 10 μgD R E P -
OVA (Figure 4B). Furthermore, it was recently pub-
lished that addition of type I IFNs do not inhibit alpha-
viral replication once RNA replication has been
established [63]. Collectively, these data suggest that
type I IFN does not act in an autocrine fashion lowering
replicon encoded antigen expression.
A role of type I IFNs is to activate negative feedback
mechanisms to avoid prolonged cytokine production
[64] and also to induce apoptosis [43,65]. These regula-
tory pathways are non-functional in IFN-AR1 KO mice
and could explain the increased CD8
+ T cell responses
in the absence of the type I IFN system. It has pre-
viously been shown that replicon induced apoptosis
increase uptake of apoptotic bodies and cross-priming
by DCs [66] and by blocking apoptosis, mice were less
protected against a subsequent tumour challenge
[43,67]. However, it was recently reported that co-deliv-
ery of pro-apoptotic genes reduced the efficacy of DNA
vaccines [68]. Hence, type I IFN induced apoptosis
could give two effects, either stimulating formation of
apoptotic vesicles, thereby stimulating cross-priming, or
lowering the antigen level produced, due to premature
cell death. If type I IFN induced apoptosis is of impor-
tance in our system, the latter scenario must be at play
in the wild type mice, lowering the antigen level and
hence the immune response.
Despite the incapability of the IFN-AR1 KO mice to
respond to type I IFNs they still produce and respond
to other cytokines induced after DREP and VREP
immunization. Hence, the robust T cell responses estab-
lished despite the lack of the adjuvant effect from type I
IFN is probably due to other effector mechanisms in
play in the IFN-AR1 KO mice, sufficient for the induc-
tion of an immune response, in combination with lack
of the negative feedback loop mediated by the type I
IFN. In accordance, it was recently published that TLR
ligands both positively and negatively modulate the
immune response after viral vector immunization [69].
In conclusion, DREP immunization results in robust T
cell responses even after a single administration and are
much stronger than those obtained by immunization
with convDNA vaccines. We found that DREP induced
T cell responses were quite similar to those induced by
VREP, suggesting that both vaccine platforms use the
same innate signalling pathways. Even though our
results could not conclude a single TLR to be crucial
for the adjuvant effect induced by SFV replicons, we
could show that IRF3, a signalling molecule downstream
of several RNA receptors, was needed for a fullminant T
cell response in VREP immunized mice, with a similar
trend in DREP immunized mice. Our data suggest that
alphaviral replicon-based vectors activate multiple innate
signalling pathways contributing to their potent immu-
nogenicity. Moreover, we show that VREP and DREP
Näslund et al. Virology Journal 2011, 8:36
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Page 7 of 9induced type I IFN restricts both primary and memory
CD8
+ T cell responses. It would seem that the efficacy
of the DREP and VREP vaccines, being RNA replicons
sensitive to host cellular responses, are dependent on a
balance between stimulatory and inhibitory signals
where replicon induced RNAs and type I IFN play an
important role.
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